Revista de Hematología

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista de Hematología >Year 2013, Issue 1

Novoa JE, Beñaran B, Rojo AL, Cuña A, Iriondo N, Calvo H, Rivero M, Cabrera A, Martínez-Colette C, Pevet M, Luongo Á, Brignoni S, Caride R, De-Bellis R
Fudarabine monophosphate as first-line treatment in chronic lymphoproliferative disorders. Multicenter study. Uruguay 1997-2012
Rev Hematol Mex 2013; 14 (1)

Language: Español
References: 16
Page: 21-25
PDF: 793.47 Kb.

Full text


Background: chronic lymphoproliferative disorders are the most common hematological malignancies in adults in the western world. Their most common clinical manifestations are chronic B lymphocytic leukemia (B-CLL) and non-Hodgkin lymphomas (NHLs), usually low grade B-cell lymphomas(NHL-LG).
Objective: to assess overall survival ,event-free complications and quality of life in patients, to suffer chronic lymphoproliferative disorders (B-CLL and low-grade NHL of malignancy) receiving fludarabine monophosphate in presentation oral or injection, as first-line treatment in a group of medical institutions in Uruguay, throughout their territory (capital and the country) during the last 15 years (1997-2012).
Patients and methods: retrospective study that evaluated overall survival at 12 years and free of events in a cohort of 351 patients with chronic lymphoproliferative disorders, B chronic lymphocytic leukemia and non-Hodgkin lymphomas of low grade, in a group of Clinical Services of the Republic of Uruguay, receiving fludarabine monophosphate oral or intravenous as first line cancer therapy.
Results: In the group of patients with chronic lymphocytic leukemia B treated with fludarabine monophosphate, the limit of overall response was 78%, with overall survival of 36% at 12 years and disease-free survival of 11% at 12 years. In the group of patients with NHL-LG overall survival at 12 years was 48% and disease free survival 44%. Oral and intravenous formulations showed no significant differences in therapeutic efficacy.
Conclusions: fludarabine monophosphate is an effective and safe drug for the treatment of B-CLL and NHL-LG. Oral and intravenous formulations show the same response in younger and older patients in this cohort of individuals with chronic lymphoproliferative disorders. It is currently being studied chemotherapeutic options combined with fludarabine.

Key words: Lymphoproliferative disorders, Fludarabine monofosfate, CLL, NHL.


  1. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.

  2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-204.

  3. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group. Blood 1996;87:4990-4997.

  4. Moreton P, Kenedy B, Lucas G, et al. Eradication of Minimal Residual Disease on Chronic Lymphocytic Leukemia after Alemtuzumab Therapy is Associated with prolongued survival. J Clin Oncol 2007;23:2971-2979.

  5. Novoa JE, Rojo AL, Beñaran B, et al. Fmf as first line therapy for chronic lymphoid leukemia. Arch Med Internal XXIX; Supl 1: March 2007 (Abstr 067).

  6. Shanafelt T. Improving treatment for patients with chronic lymphocytic leukemia. Hematology 2012;17:133-136.

  7. Bird JC, Rai K, Peterson BL, et al. The addition of rituximab to fludarabine may prolong progression –free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.

  8. Keating MJ, O’Brien S, Alvitar M, et al. Early result of chemoimmunotherapy regimen of Fludarabina, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.

  9. Hallek M, Fisher K, Fingerle-Rawson G, et al. Addition of rituximab to fludarabine and Cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized opern-label, phase 3 trial. Lancet 2010;376:1164-1174.

  10. Ferrajoli A, O’Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005;46:S87.

  11. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109:2291-2298.

  12. Gerrie AS, Toze CL, Ramadan KM, et al. Oral fludarabine and rituximab as initial therapy for Chronic lymphocytic leukemia or small lymphocytic lymphoma: population based experience matches clinical trials. Leuk Lymphoma 2012;53(1):77-82.

  13. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313-4320.

  14. Burguer JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-Cell malignancies: a target for new treatment strategies. Blood 2009;114(16):3367-3375.

  15. Shanafelt TD, Tun HW, Hanson CA, et al. Lenalidomide consolidation appears to prolong time to retreatment after first line chemoimmunotherapy for patients with previously untreated CLL. Blood 2011;118. Abstract 3899.

  16. Shanafelt TD, Lanasa MC, Zent CS, et al. Ofatumumab based chemioimmunotherapy (CIT) for patients with previously untreated CLL. Blood 2011;118. Abstract 3898

>Journals >Revista de Hematología >Year 2013, Issue 1

· Journal Index 
· Links 

Copyright 2019